Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 4

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

NCT06883123 · View on ClinicalTrials.gov ↗

Study Summary

A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.

Conditions Studied

Interventions

  • DRUG Latanoprost 0.005% Ophthalmic Solution
  • DRUG Simbrinza 0.2%-1% Ophthalmic Suspension
  • DRUG Rocklatan 0.02%-0.005% Ophthalmic Solution
  • DRUG Cosopt PF 2%-0.5% Ophthalmic Solution

Study Locations (1)

Illinois

  • Prairie Eye Center — Springfield

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2025-05-14
Est. Completion 2026-04-01
Phase Phase 4

Sponsor

Prairie Eye Center

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06883123

The ClinicalTrials.gov registry entry for NCT06883123 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prairie Eye Center, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Open Angle Glaucoma appearing as the primary indexed condition, and to 4 interventions — of which Latanoprost 0.005% Ophthalmic Solution is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06883123 reports 1 study location spanning 1 distinct geographic area — top geographies include Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06883123 about?

NCT06883123 is a clinical study titled "Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost". A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.

What is the current status of trial NCT06883123?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2025-05-14. Estimated completion is 2026-04-01.

What conditions does trial NCT06883123 study?

This clinical trial studies the following conditions: Open Angle Glaucoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06883123?

The interventions under investigation include: Latanoprost 0.005% Ophthalmic Solution (DRUG), Simbrinza 0.2%-1% Ophthalmic Suspension (DRUG), Rocklatan 0.02%-0.005% Ophthalmic Solution (DRUG), Cosopt PF 2%-0.5% Ophthalmic Solution (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06883123?

This trial is sponsored by Prairie Eye Center, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06883123 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial